In May 2018, through the U.S. Trotting Association Board of Directors Medication Subcommittee, the USTA established the Harness Racing Medication Collaborative to develop reliable, consistent medication regulations for application specifically to harness racing. On Wednesday (Nov. 28), the HRMC distributed usage recommendations supported with position papers for thresholds and withdrawal times on two therapeutic medications, clenbuterol and betamethasone, to 16 state regulatory agencies. “The HRMC will close a gap in the science and policy underlying Standardbred medication regulation,” said USTA President Russell Williams in making the announcement last May. “Our primary goal is to improve the quality of medication information available to our regulators.”